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Although spontaneous remyelination does occur in multiple sclerosis lesions, its extent within the global
population with this disease is presently unknown. We have systematically analysed the incidence and distribu-
tion of completely remyelinated lesions (so-called shadow plaques) or partially remyelinated lesions (shadow
plaque areas) in 51 autopsies of patients with different clinical courses and disease durations. The extent of
remyelination was variable between cases. In 20% of the patients, the extent of remyelination was extensive
with 60–96% of the global lesion area remyelinated. Extensive remyelination was found not only in patients with
relapsing multiple sclerosis, but also in a subset of patients with progressive disease. Older age at death and
longer disease duration were associated with significantly more remyelinated lesions or lesion areas. No
correlation was found between the extent of remyelination and either gender or age at disease onset.
These results suggest that the variable and patient-dependent extent of remyelination must be considered
in the design of future clinical trials aimed at promoting CNS repair.
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Introduction
Multiple sclerosis is an inflammatory CNS disease associated
with focal white matter plaques of demyelination (Charcot,
1868; Lumsden, 1970). Plaques can in part become repaired
by remyelination. Reappearance of oligodendrocytes within
active lesions associated with early stages of remyelination
are frequently seen in patients with acute or early multiple
sclerosis (Lassmann, 1983; Prineas et al. 1984; Prineas, 1985;
Raine and Wu, 1993; Prineas et al. 1993a; Bruck et al.,
1994; Lucchinetti et al., 1999). This may give rise to com-
pletely remyelinated plaques, the so called shadow plaques
(Schlesinger, 1909; Lassmann, 1983; Prineas, 1985). It has,
however, been suggested that remyelination is a transient
phenomenon (Frohman et al., 2006) and that remyelinated
shadow plaques may become affected by new bouts of
demyelination (Prineas et al., 1993b). In patients with late
stage progressive disease, remyelination is thought to be
sparse and largely restricted to a small zone at the borders
of inactive plaques (Suzuki, 1969). Yet, in a correlative
radiological-pathological study in autopsy brains, remyeli-
nated areas were found in 42% of the lesions studied. Partial
remyelination was observed in 19% of the lesions and 23% of
the lesions were completely remyelinated shadow plaques
(Barkhof et al., 2003). Due to these divergent results a sys-
tematic study of remyelination at different stages and in
different forms of multiple sclerosis seems to be necessary.
Since there is no established and reliable surrogate MRI
marker of remyelination, it is still necessary to rely on post-
mortem histopathological analysis. In this study we observed
that in some patients remyelination is extensive, whereas in
others it largely fails. Patients who had died at an older age
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 and after a longer disease duration showed more extensive
remyelination when compared to those who died earlier in
the disease course.
Patients and methods
Brain tissue from 51 multiple sclerosis cases, comprising 5 acute,
7 relapsing–remitting, 18 secondary progressive and 11 primary
progressive cases, and 10 cases with an unknown clinical course,
was analysed for evidence and extent of remyelination. The average
age at death was 49.96 years (range 20–75), the female to male ratio
1.5:1, andthe average disease duration was 175.21months (0.6–708).
Clinical records, which allowed for an unequivocal identification
of disease course, were available from 41 of the total 51 patients
and for all patients with large hemispheric or double hemispheric
brain sections. The other 10 patients died in the progressive phase
of the disease but could not be classified as primary or secondary
progressive. Patient demographics are given in Table 1. Clinical
courses were determined by retrospective chart reviews performed
either by a neurologist (H.R., P.S.S. and C.L.) or a neuropathologist
(C.S.), blinded to the outcome of our neuropathological analysis.
Our study was restricted to the analysis of the forebrain. A total
of 1026 lesions were analysed. Whole hemispheric or double
hemispheric brain sections were performed for 23 cases. Double
hemispheric sections were obtained in a standardized fashion,
including one section at the level of the anterior part of the corpus
callosum and one at the level of the mid thalamus. Single hemi-
spheric brain slices were available from multiple brain regions,
including the frontal, parietal and occipital lobe. Depending on
the macroscopic identification of demyelinated lesions additional
small tissue blocks were taken from various regions of the forebrain
(see also Table 2). For the remaining cases multiple regular tissue
blocks (average number of small sections per case = 3.97, approx-
imate average size = 2 · 3c m
2) formed the basis of the analysis.
Brains were fixed in formaldehyde and embedded in paraffin. In
three of the cases, tissue blocks, which were fixed in glutaraldehyde
and embedded in epoxy resin, were available for analysis in
addition to the paraffin embedded material. Paraffin sections
from all cases were stained with haematoxylin and eosin, Luxol
fast blue, Bielschowsky’s silver stain and by immunocytochemistry
for proteolipid protein (PLP) or myelin basic protein (MBP). The
epoxy-embedded sections were stained with Toluidine blue.
Immunocytochemistry
Immunocytochemistry was performed using an avidin/biotin
method. Sections were de-paraffinized, and antigen retrieval was
performed in a steamer for 90 min with EDTA buffer at pH 8.5.
Primary antibodies against the following targets were used: PLP
(polyclonal, Serotec, Oxford, UK; AHP 261; monoclonal, Serotec,
Oxford, UK; MCA839G), MBP (polyclonal, DAKO, Glostrup,
Denmark A0623), neurofilament (polyclonal; Chemicon, Temecula,
USA; AB1983; monoclonal; Affinity, Mamhead, UK; SMI 31 and
SMI 33) and the macrophage antigen CD68 (monoclonal, DAKO,
M0814). Incubation of the sections with primary antibodies over-
night at 4C was followed by application of biotinylated secondary
antibodies (sheep anti-mouse or donkey anti-rabbit, Amersham,
Buckinghamshire, UK; RPN 1001 and 1004) and peroxidase labelled
avidin (Sigma, St Louis, USA; A3151). Bound antibodies were visua-
lized by developing the sections with diaminobenzidine and nickel.
Immunocytochemical double staining was performed for conven-
tional light microscopy. In a first step, myelin antigens were labelled
by polyclonal antibodies against PLP or MBP. Then, neurofilament
epitopes were stained with a mixture of the monoclonal antibodies
SMI 31 and 33. Rabbit polyclonal antibodies were detected with an
alkaline phosphatase labelled donkey anti-rabbit antibody (Jackson
ImmunoResearch, West Grove, USA; 59678) using fast red BB salt as
chromogen. Finally, the sections were incubated with biotinylated
sheep anti-mouse antibody and avidin peroxidase. The reaction
product was visualized with diaminobenzidine.
In addition confocal laser microscopy was performed for double
and triple staining. Myelin was stained with polyclonal primary
antibodies against PLP or MBP and bound antibodies were visua-
lized with biotinylated donkey anti-rabbit (Amersham, Oxford, UK;
RPN1004) and Cy
TM2 labelled streptavidin (Jackson Immuno-
Research, West Grove, USA; 59678). Neurofilaments were stained
with a mixture of SMI 31 and 33 mouse monoclonal antibodies and
aC y
TM3 donkey anti-mouse antibody (Jackson ImmunoResearch,
Dianova, Hamburg; 715-165-151). For active lesions we additionally
used the monoclonal antibody against CD68, which was then visua-
lized with an Alexa Fluor 660 goat anti-mouse secondary antibody
(Molecular Probes, Eugene, OR, USA; A21055).
Table 1 Clinical data of all cases
Clinical subtypes Age onset (years) Age at death (years) Disease duration (months) Female:male
Acute 45 (35–51) 45 (35–51) 3.4 (0.6–7) 0.67:1
RRMS 31 (16–48) 49 (20–67) 136 (48–234) 0.50:1
SPMS 31 (19–50) 48 (34–71) 204 (72–408) 1.70:1
PPMS 39 (25–49) 55 (28–75) 188 (30–411) 1.75:1
Unknown 14, 47 51 (42–73) 108, 708 3.50:1
Averages shown with range in parentheses. Disease duration in months. Only two disease durations known in the unknown clinical course
group.
RR = relapsing-remitting; SP = secondary progressive; PP = primary progressive; MS = multiple sclerosis.
Table 2 Sub-study showing the percentage of
remyelination in large versus small sections
Case no. Large sections Small sections
1 84 (2) 71 (5)
2 78 (1) 71 (6)
3 85 (1) 80 (5)
4 8 (2) 2 (6)
5 9 (2) 15 (13)
6 5 (1) 0 (3)
Number of sections in parentheses.
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 For control, sections were reacted in the absence of primary
antibodies or by using irrelevant primary antibodies of the same
immunoglobulin subclass.
Strategy for quantitative analysis of
remyelination
Shadow plaques and shadow plaque areas (incomplete shadow pla-
ques), defined according to the criteria described in the Results
section, were first identified on consecutive sections stained with
Luxol fast blue (LFB) and by immunocytochemistry for PLP. When
such lesions were present, sections from two representative tissue
blocks per case were double stained for confocal laser microscopy
and by conventional immunocytochemistry to confirm the presence
of remyelination. In the three cases where additional epoxy resin
embedded material was available, remyelination was further
confirmed in plastic sections of osmicated material. Sections were
digitally scanned, printed, and the areas of demyelination and
remyelination were labelled. The images were overlaid by a morpho-
metric grid and the number of grid-points located over the total
white matter area, as well as the area of demyelinated or remyeli-
nated plaques, was determined. To analyse the relation between
total plaque size and remyelination, correction was made for the
enlargement of the images and all data were standardized to the
actual mm
2 of tissue area. The extent of remyelination was then
expressed as the percentage of the total plaque area.
Determination of the extent of remyelination may be biased
when the analysis is performed on small tissue blocks, which
were macroscopically selected for the presence of demyelination.
In order to assess the reliability and consistency of our quantitative
methods, we also compared in a sub-study on six patients the
extent of remyelination in hemispheric or bi-hemispheric sections
with the extent of remyelination in randomly sampled small MS
blocks of the same case. The percentage of remyelination within the
total lesions was overall comparable in small sections to that seen
in the large sections when >3 small sections were used (Table 1).
It was noted, however, that the extent of remyelination in most
small sections is slightly underestimated compared to that seen in
the large sections, likely reflecting a tissue sampling bias.
Statistical analysis
Statistical analysis was performed using Statgraphics Plus 4.0.
Spearman’s rank correlations were used to identify interdependence
of variables, comparing remyelination, age at disease onset, disease
duration and age at death. Group differences were analysed using
non-parametric group tests (Kruskal–Wallis) to compare genders,
high and low remyelination cases, and the different clinical subtypes.
P-values of <0.05 were considered significant.
Results
Definition of remyelinated areas in the
brains of multiple sclerosis patients
Previous studies on the fine structure of multiple sclerosis
lesions have defined areas of remyelination based on the
abundance of thinly myelinated fibres with shortened inter-
nodes and widened nodes of Ranvier (Prineas, 1985). In
conventional myelin stains of such lesions, remyelination
appears as focal areas with reduced myelin density when
compared to the surrounding normal appearing white matter
(shadow plaques; Fig. 1E and F). These lesions are sharply
demarcated from the surrounding normal appearing white
matter and generally centred on a small or medium sized
vein. The pale myelin stain is due to a uniform reduction
of myelin sheath thickness throughout the whole lesion
and both shortened internodes and widened nodes of
Ranvier can be detected by inspection at high magnification
(Fig. 1I, J, L and M). Other characteristic features of
shadow plaques were a moderate reduction of axonal density
(Kornek et al., 2000), the absence of macrophages with early
myelin degradation products (Fig. 1I and J) and a low
number of perivascular inflammatory infiltrates. In addition,
in cases with profound remyelination, which still contained
actively demyelinating lesions (Fig. 1C and D), the whole
spectrum of remyelination was seen. Complete demyelination
was present in classical active lesions (Fig. 1H), which
contained abundant macrophages with early myelin degrada-
tion products. In lesions, which were still hypercellular
and infiltrated by macrophages with empty vacuoles, small
clusters of thin myelin sheaths were found which were only
detectable by immunocytochemistry for PLP (Fig. 1I). Other
plaques with only minimal residual macrophage infiltration
contained abundant axons with very thin PLP reactive myelin
sheaths with only faint staining for LFB (Fig. 1J). These
lesions were present together with classical shadow plaques
within the same case or section.
However, focally reduced myelin density within multiple
sclerosis brains can also occur for reasons other than remye-
lination. Actively demyelinating lesions are also sharply
demarcated areas of reduced myelin density; however,
these lesions are infiltrated by macrophages with early myelin
degradation products and the remaining myelin sheaths
within the lesions are of comparable thickness to those in
the surrounding white matter and may show signs of dis-
solution (Fig. 1N–P). Another possible reason for reduced
myelin density around an established plaque may reflect
Wallerian degeneration, due to axonal destruction and loss
within the lesion. Such areas of secondary degeneration are
poorly demarcated areas of reduced myelin density, sur-
rounding the plaques in ill-defined contours (Fig. 1Q–S).
At higher magnification, a profound reduction of axonal
density is seen and the remaining fibres are enveloped by
myelin sheaths, which are similar in thickness when com-
pared to those in the surrounding normal appearing white
matter. Sometimes they may reveal an unusually high density
of thick myelinated fibres, since thin axons are preferentially
destroyed in multiple sclerosis lesions (Evangelou et al.,
2001).
In our further quantitative studies, only those lesions
with reduced myelin density were included which fulfilled
the criteria for remyelinated shadow plaques or shadow pla-
que areas as defined above. Shadow plaques contained uni-
formly thin myelin sheaths throughout the whole lesion,
while shadow plaque areas (incomplete shadow plaques)
only affected part of the lesions.
Remyelination in multiple sclerosis Brain (2006), 129, 3165–3172 3167
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 Distribution of shadow plaques and extent
of remyelination
Major differences in the incidence of shadow plaques and in
the extent of remyelination became apparent between indi-
vidual patients (Fig. 1A–D). In 10 patients most focal plaques
within the forebrain were shadow plaques, resulting in 60–
96% of total plaque area being remyelinated (Fig. 1C and D;
Table 3). In 34 other patients, remyelination was sparse
and restricted to small zones at the edge of demyelinated
lesions leading to a total percentage of remyelinated areas
between 0 and 25% (Fig. 1A and B; Table 3). The remaining
seven patients had an intermediate range with a percentage
of remyelination between 25 and 60% of the plaque area
(Table 3). Similar results were also obtained when the analysis
was restricted to cases where large hemispheric or double
hemispheric sections were available (Table 4), however,
most of these large-section cases segregated into two distinct
groups of either high or low remyelination (Fig. 2B). There
was no significant difference between the total plaque area
analysed in the high versus low remyelinating cases either
when all cases were analysed (P = 0.41) or when the cases
of acute disease were excluded from the analysis (P = 0.14).
The extent of remyelination was in part dependent upon
the location of the lesion. Although complete remyelination
was present in some periventricular plaques, the global extent
of remyelination was lower in these lesions compared to
those located in the deep white matter or subcortically
(Fig. 1E and F; Tables 4 and 5). This was seen not only in
the global multiple sclerosis sample, but also in cases with a
high extent of remyelination, in whom large (hemispheric or
double hemispheric) sections were available.
Relation between extent of shadow
plaque formation and clinical course of
the disease
Shadow plaque areas were rare in acute cases, accounting for
only 0–13% of total plaque area. This may have been due to
the fact that most lesions examined were in a stage of early
active demyelination (Kutzelnigg et al., 2005). However, as
described previously (Lucchinetti et al., 1999), in many of
these lesions activated oligodendrocytes with signs of early
myelin formation were seen.
The frequency and size of shadow plaques or shadow
areas were highly variable between different patients with
chronic illness. They were more frequent in patients with
relapsing–remitting and primary progressive disease com-
pared to those with secondary progressive illness, but these
differences did not reach statistical significance (Tables 3
and 4). We did not find a significant correlation between
the extent of shadow plaque formation with either the age
of disease onset or gender in the global sample or when acute
cases were excluded from the analysis. However, there was a
significant correlation (P = 0.017, r = 0.34) between the
extent of remyelinated plaque area and the age of death of
the patients. Those patients who died at an older age showed
significantly more shadow plaques or shadow plaque areas
compared to those who died at a younger age (Fig. 2A). This
was also seen when acute patients were excluded from the
analysis (P = 0.03; r = 0.32). A similar correlation was found
when only the large hemispheric or double hemispheric
sections were analysed (P = 0.026, r = 0.48; Fig. 2B). A sig-
nificant correlation was also found between remyelination
and disease duration (P = 0.021, r = 0.38), as shown in Fig. 3.
Fig. 1 (A–D) Schematic diagrams showing the proportion of remyelination (blue) and demyelination (red) in different MS patients.
(A) Case 12; SPMS with 8% RM, (B) Case 11; SPMS with 24% RM, (C) Case 5; RRMS with overall 78% RM, and (D) Case 19; PPMS with
overall 84% RM. The rows below the schematic diagrams show the features differentiating remyelination from active MS plaques and axonal
loss secondary to Wallerian degeneration. (E) Case 21; PPMS; PLP stained section (low power view) showing sharply demarcated
demyelinated and shadow plaques; the periventricular lesion is completely demyelinated in the periventricular area (D), but contains a large
shadow plaque area in the rest of the plaque (SA); most of the lesions in the deep white matter are sharply demarcated shadow plaques (S);
·3. (F) In the consecutive sections stained with LFB pale myelin stain is seen in the shadow plaques and plaque areas; ·3. (G) Case 19;
PPMS; high power view of PLP staining in the normal appearing white matter of the same case, shown in H–L; ·100. (H) PLP stained
section of an active plaque showing macrophages containing myelin degradation products; there is no remyelination in this lesion; ·200.
(I) PLP stain showing early remyelination with clusters of very thin sheaths in a lesion, which is still hypercellular; ·200. (J) later
stage of remyelination showing abundant thin myelin sheaths; ·150. (K) Confocal fluorescence image of PLP (red) and axonal neurofilaments
(SMI 31 and 33 stained green) showing thick myelin sheaths in normal appearing white matter adjacent to the lesion, depicted
in L; ·800. (L) same section as in (K) showing thin myelin sheaths enveloping axons in a shadow plaque; note the widened node of Ranvier
(asterisks); ·800. (M) Case 5; RRMS; Toluidine blue stain showing thin myelin sheaths and a widened node of Ranvier; ·800.
Further features of acute plaques (Case 3; acute): (N) LFB low power view showing reduced myelin staining and a sharply demarcated
border; ·15; (O) higher power view showing massive macrophage infiltration; ·150; (P) confocal fluorescence image of PLP (red),
CD68 stained macrophages (blue), and SMI 31 and 33 neurofilament stainings (aqua) showing abundant macrophages with myelin
degradation as well as myelinated and demyelinated axons; ·300. Features of Wallerian degeneration (WD) secondary to axonal injury:
(Q) Case 4; RRMS; LFB low power view of a plaque (PL) in a patient with acute MS and extremely destructive white matter lesions,
which is surrounded by Wallerian degeneration showing the reduced myelin staining and an indistinct border; ·3; (R) Bielschowsky’s
silver stain showing reduced axonal densities surrounding the plaque; ·3; (S) Case 7; RRMS; confocal fluorescence image with
PLP (green) and neurofilaments (SMI 31 and 33 stained red) showing reduced axonal density and axolysis, namely hollow myelin
sheaths and alterations in axonal diameters; ·700. RR = relapsing-remitting; SP = secondary progressive; PP = primary progressive;
MS = multiple sclerosis.
Remyelination in multiple sclerosis Brain (2006), 129, 3165–3172 3169
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 Discussion
Three key observations are reported in our study. Remyelina-
tion, defined by the presence of shadow plaques, is extensive
in a considerable proportion of multiple sclerosis patients.
It is not restricted to early stages of the disease and it occurs
in all manifestations of the disease, including primary pro-
gressive multiple sclerosis.
It was first suggested by Marburg (1906) that spontaneous
remyelination may occur in multiple sclerosis. This was later
confirmed when electron microscopy was introduced into
multiple sclerosis research (Perier and Gregoire, 1965;
Suzuki et al., 1969). In the following years it became clear
that shadow plaques, originally identified by Schlesinger in
1909 as areas of incomplete demyelination, represent fully
remyelinated plaques (Lassmann, 1983; Prineas, 1985).
Table 4 Lesion distribution in large tissue sections
Case Type Age Disease duration
(months)
Periventricular Deep WM Subcortical Total RM%
SP ISP DM SP ISP DM SP ISP DM
1 Ac 35 1.5 5 15 20 0
2A c4 6 3 1 10
3 Ac 51 5 19 17 7 92 135 13
4R R2 04 8 1 3 2 8 4 10
5 RR 34 156 2 1 47 11 11 3 1 76 78
6 RR 40 120 2 1 2 5 0
7 RR 58 120 2 1 1 4 81
8 RR 60 234 6 1 8 1 1 17 85
9 SP 35 n.a. 4 4 13 12 15 20 3 2 73 9
10 SP 41 156 1 5 5 1 3 3 18 5
11 SP 43 192 3 1 10 4 9 27 24
12 SP 45 240 1 1 1 25 1 9 38 8
13 SP 46 n.a. 1 2 2 5 10 20
14 SP 46 264 6 11 6 23 0
15 SP 53 241 2 5 4 6 1 18 3
16 SP 55 366 4 5 7 1 7 3 6 33 8
17 SP 56 408 4 4 1 9 50
18 SP 70 120 1 1 2 2 1 7 61
19 PP 55 150 5 2 84 12 16 12 3 134 84
20 PP 56 132 1 5 2 1 9 53
21 PP 68 336 2 5 6 7 1 6 4 31 60
22 PP 72 411 2 1 4 19 1 5 32 81
23 PP 75 314 2 1 3 0
SP = shadow plaques; ISP = incomplete shadow plaques (demyelinated plaques with shadow plaque areas); DM = demyelinated plaques; Ac =
acute multiple sclerosis (MS); RR = relapsing/remitting MS; SP = secondary progressive MS; PP = primary progressive MS; RM% = percentage of
remyelinated area in all lesions; WM = white matter; n.a.: not available.
Age at death
R
M
%
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100 (a)
(b)
Age at death
R
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0
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40
60
80
100
Fig. 2 Graph showing the statistically significant correlation of
increased remyelination with increased age at death in (A) the
global sample (n = 50; P = 0.017; r = 0.34) and (B) in patients where
large hemispheric or bi-hemispheric sections were available
(n = 23; P = 0.026; r = 0.48).
Table 3 Distribution of numbers of cases (n = 51) from all
clinical subtypes into the different remyelination groups
Clinical subtypes 0–25% 26–59% 60–100%
Acute 5 0 0
RRMS 4 0 3
SPMS 14 3 1
PPMS 7 1 3
Unknown 4 3 3
Total 34 7 10
RR = relapsing-remitting; SP = secondary progressive; PP = primary
progressive; MS = multiple sclerosis.
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 Remyelination starts early after onset of demyelination and,
indeed, many active lesions show signs of oligodendrocyte
activation and initial stages of remyelination whilst still
containing macrophages loaded with myelin degradation
products (Prineas et al., 1993a; Raine and Wu, 1993;
Lucchinetti et al., 1999; Wolswijk, 2000). From these studies
it was concluded that remyelination transiently occurs during
the acute and early relapsing stage of the disease, being sparse
or absent in patients with late chronic disease (Prineas et al.,
1993a; Ozawa et al., 1994; Frohman et al., 2006).
Contrary to these earlier studies we found that extensive
remyelination is present in a subset of patients with chronic
multiple sclerosis and that in such patients virtually all inac-
tive white matter plaques are remyelinated shadow plaques.
In our global sample we found a profound diversity in the
amount of remyelination between cases. However, when the
analysis was restricted to patients where large hemispheric or
bi-hemispheric sections were available, they clearly segregated
into two groups with either extensive or low remyelinating
capacity. Why this dichotomy was only visible in the sub-
study based on large sections is not clear so far. Although we
were able to show that the extent of remyelination overall was
comparable in case samples with large and small sections, we
can not exclude that the extent of remyelination is at least in
part underestimated when only small tissue blocks are used,
which are selected on the basis of macroscopically visible
lesions. Alternatively, the smaller number of cases in
whom large sections were available may confer a sampling
bias. In addition, we used a stringent classification for
remyelinated shadow plaques. Thus we excluded all lesions
or lesion areas which were suggestive of secondary Wallerian
tract degeneration as well as actively demyelinating plaques,
which also contain some remyelination. Thus, the global
extent of remyelination in our study is rather underestimated
than exaggerated.
It is unresolved as to why in some patients remyelination is
widespread whilst in others it is sparse (Franklin, 2002).
Several mechanisms have been suggested that may result in
blockade of remyelination in multiple sclerosis. These include
the loss and destruction of oligodendrocyte progenitor cells
within the lesions in the course of repeated de- and remye-
lination (Prineas et al., 1993b). In some lesions, however,
progenitor cells are abundantly present (Chang et al., 2000;
Chang et al., 2002), but they may fail either because the axons
are not permissive for remyelination (Charles et al., 2002) or
the maturation of progenitor cells is inhibited (John et al.,
2002). Whether the extent of remyelination depends upon the
genetic background of the patients has yet to be determined.
According to our results shadow plaques were not
restricted to patients with early and relapsing disease, but
were prominent in patients with long-standing chronic dis-
ease, who died at old age. However, this diverse capacity to
form shadow plaques did not correlate with clinical subtype,
age of disease onset or gender. The incidence of active demye-
lination in focal white matter plaques in general decreases
with chronicity of the disease (Kutzelnigg et al., 2005). In
early stages the illness, remyelination occurs in lesions, which
are either still active or may be subjected to repeated de- and
remyelination (Prineas et al., 1993b). Such remyelination
may be unstable and the formation of persistent shadow
plaques may be sparse in contrast to that in inactive lesions
at the late stage of the disease. Another factor, which seems
to determine remyelination in a given lesion, is its location.
We found more remyelination in lesions located subcortic-
ally or in the deep white matter than in periventricular
plaques. The reason for this difference is currently not
clear. Finally, we have shown before that remyelination pro-
tects against progressive axonal injury (Kornek et al., 2000).
Thus, completely demyelinated in contrast to remyelinated
plaques may progressively shrink, thus increasing the relative
percentage of remyelinated areas in patients with long-
standing multiple sclerosis. Although this factor may contri-
bute to our findings in some patients, it is unlikely to be a
major factor in patients with a very high extent of remyelina-
tion. In these patients we found that complete demyelination
is only present in lesions with recent demyelinating activity
(see Fig. 1C and D).
Our study shows that remyelination in focal white matter
plaques is extensive in a subset of multiple sclerosis lesions.
Although functional restoration of conduction has been
shown by electrophysiology in some lesions (Kriss et al.,
1988), it is currently undetermined as to what extent this
Table 5 Percentage of plaque types and total number of
plaques in different brain regions in all cases versus
high remyelinators with large sections (>50% global
remyelination)
All cases SP% ISP% DM% Total plaques
Periventricular 10.8 30.6 58.6 196
Other plaques 38.2 12.0 49.8 830
Cases with extensive remyelination
Periventricular 40.9 22.7 36.4 44
Other plaques 70.2 10.9 18.9 275
SP = shadow plaque; ISP = incomplete shadow plaque;
DM = demyelinated plaque.
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Fig. 3 Graph showing the statistically significant correlation
between remyelination and disease duration (global sample;
n = 39; P = 0.021; r = 0.374).
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 occurs in the global multiple sclerosis population. In this
context it is important to note that our study was restricted
to the analysis of forebrain lesions. Whether the remyelinat-
ing capacity of lesions is regionally different in the human
brain and spinal cord awaits further investigation. Despite
this caveat, new paraclinical tools have to be developed
to assess the extent of spontaneous remyelination in the
context of therapeutic trials aimed to promote remyelination
in multiple sclerosis.
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